# AQUILA (NCT03301220)

> A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03301220
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Smoldering Multiple Myeloma
- Interventions: Daratumumab SC: daratumumab + rHuPH20
- Enrollment: 390
- Primary outcome: Progression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)

## Questions raised in the commentary

_Automated from the 40 newest of 362 indexed sources (Apr 2026 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether early treatment is appropriate or active monitoring remains reasonable
- How high-risk smoldering myeloma should be defined
- Whether early treatment improves outcomes beyond delaying progression
- How daratumumab compares with more intensive early-treatment approaches

## Indexed commentary on AQUILA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 151
- YouTube: 127
- Podcasts: 50
- Bluesky threads: 27
- X videos: 7

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=aquila-nct03301220

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03301220", "email": "<work email>"}; the inbox owner confirms by the emailed link.